Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Macular Degeneration
Regeneron Receives $20 Million Milestone Payment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD
August 27th, 2007
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that it has received a $20 million milestone payment from Bayer HealthCare following dosing of the first patient in the Phase 3 study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD). "Age-related macular degeneration continues to be one of the leading causes of blindness in adults today," said Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer of Regeneron. "Results of early phase studies have shown that VEGF Trap-Eye has the potential to be an important addition to the treatment alternatives available for patients with wet AMD. We are especially...
Source: Clinical Trials Week (2007-08-27)
|
